reports
Comfort Systems Usa Inc: 3 directors
Two Directors at Comfort Systems Usa Inc sold 6,287 shares at between 1,369.742USD and 1,419.800USD. The significance rating of the trade was 80/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's direct...
Installed Building Products Inc: 1 director
A director at Installed Building Products Inc sold/sold after exercising options 400,000 shares at 314.060USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the com...
United States Lime & Minerals Inc: 1 director
A director at United States Lime & Minerals Inc sold 1,277 shares at 120.450USD and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last...
Vericel Announces FDA Approval of New State-of-the-Art Advanced Therap...
Vericel Announces FDA Approval of New State-of-the-Art Advanced Therapy Manufacturing Facility Company Achieves Significant Regulatory and Operational Milestone Substantially Increases Manufacturing Capacity to Support Long-Term Growth Enables Potential MACI Commercialization Outside of the U.S. CAMBRIDGE, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for MACI® (autologous cultured chond...
- Jonathan Moreland
ZBRA ZEBRA TECHNOLOGIES CORPORATION CLASS A
XRAY DENTSPLY SIRONA INC.
VNO VORNADO REALTY TRUST
TCBI TEXAS CAPITAL BANCSHARES INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
MTDR MATADOR RESOURCES COMPANY
FFIN FIRST FINANCIAL BANKSHARES INC
WD WALKER & DUNLOP INC.
AUP AURINIA PHARMACEUTICALS INC.
SABR SABRE CORP.
TREX TREX COMPANY INC.
AJG ARTHUR J. GALLAGHER & CO.
KKR KKR & CO. INC.
SMCI SUPER MICRO COMPUTER
AHCO INC.
DCTH ADAPTHEALTH
TSLX DELCATH SYSTEMS
THRY SIXTH STREET SPECIALTY LENDING
EOSE INC.
AGL THRYV HOLDINGS
FRSH EOS ENERGY ENTERPRISES INC (A)
FA AGILON HEALTH
CMTG INC.
MYN FRESHWORKS INC.
WRB FIRST ADVANTAGE CORP NEW
BLCO CLAROS MORTGAGE TRUST
NMTC INC.
MSDL BLACKROCK MUNIYELD N Y INSD FD INC
LAW W.R. BERKLEY CORPORATION
BAUSCH + LOMB CORP
NEUROONE MEDICAL TECHNOLOGIES CORP
MORGAN STANLEY DIRECT LENDING
CS DISCO INC
Trex Co Inc: 1 director
A director at Trex Co Inc bought 12,380 shares at 40.675USD and the significance rating of the trade was 96/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly s...
Vericel to Present at Multiple Upcoming Investor Conferences
Vericel to Present at Multiple Upcoming Investor Conferences CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the Company will present at the following investor conferences: TD Cowen 46th Annual Healthcare Conference on Wednesday, March 4th, 2026Leerink Partners 2026 Global Healthcare Conference on Tuesday, March 10th, 2026 A webcast of the presentations will be available on the Investor Relations section of the Vericel Corporation website at: ...
- Jonathan Moreland
TBK TRIUMPH BANCORP INC.
MELI MERCADOLIBRE INC.
HTGC HERCULES CAPITAL INC.
AXTI AXT INC.
LFVN LIFEVANTAGE
HRI HERC HOLDINGS INC.
SXC SUNCOKE ENERGY INC.
CSWC CAPITAL SOUTHWEST CORP.
WINA WINMARK CORP.
AWI ARMSTRONG WORLD INDUSTRIES
PCB INC.
IDYA PACIFIC CITY FINANCIAL CORP
FOUR IDEAYA BIOSCIENCES
LRMR SHIFT4 PAYMENTS
PCVX INC.
ABCL LARIMAR THERAPEUTICS INC
ACVA VAXCYTE
TBBK ABCELLERA BIOLOGICS
FSCO ACV AUCTIONS INC.
ZURA THE BANCORP
NPWR INC.
EDSA FS CREDIT OPPORTUNITIES CORP.
LAW ZURA BIO LTD
NET POWER INC
EDESA BIOTECH INC
CS DISCO INC
ADMA Biologics Announces $125 Million Accelerated Share Repurchase wit...
ADMA Biologics Announces $125 Million Accelerated Share Repurchase with JPMorgan as Part of a Planned $200 Million 2026 Total Share Repurchase Initiative RAMSEY, N.J. and BOCA RATON, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced a capital return initiative target of approximately $200 million during 2026, including the execution of a $125 million accelerated share repurchase (“ASR”)...
- Wedbush Research
UBI UBISOFT ENTERTAINMENT SA
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
TRIP TRIPADVISOR INC.
SRPT SAREPTA THERAPEUTICS INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
MELI MERCADOLIBRE INC.
KURA KURA ONCOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
GERN GERON CORP.
FB FACEBOOK INC. CLASS A
FATE FATE THERAPEUTICS INC
EXPE EXPEDIA GROUP INC.
ETSY ETSY INC.
EBAY EBAY INC.
CTMX CYTOMX THERAPEUTICS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
CDR CD PROJEKT S.A.
FRX_CN FENNEC PHARMACEUTICALS
7974 NINTENDO CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
EA ELECTRONIC ARTS INC.
PTGX PROTAGONIST THERAPEUTICS
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
OVID OVID THERAPEUTICS
ISR ISORAY
SE SEA ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
APLS APELLIS PHARMACEUTICALS
BKNG BOOKING HOLDINGS INC.
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
STRO SUTRO BIOPHARMA
LYFT LYFT
PINS PINTEREST INC. CLASS A
UBER UBER TECHNOLOGIES INC.
CHWY CHEWY INC. CLASS A
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
IDYA INC.
PASG IDEAYA BIOSCIENCES
BDTX PASSAGE BIO
ACET BLACK DIAMOND THERAPEUTICS
KROS ADICET BIO INC
ZNTL KEROS THERAPEUTICS
BEAM ZENTALIS PHARMACEUTICALS
LRMR BEAM THERAPEUTICS
OCUP LARIMAR THERAPEUTICS INC
PRAX OCUPHIRE PHARMA INC
COGT PRAXIS PRECISION MEDICINES
U COGENT BIOSCIENCES INC
TVTX UNITY SOFTWARE
DASH TRAVERE THERAPEUTICS INC
ABNB DOORDASH
VRDN AIRBNB INC. CLASS A
PLTK VIRIDIAN THERAPEUTICS INC
NUVB PLAYTIKA HOLDING
RBLX NUVATION BIO INC (A)
DAWN ROBLOX
TNGX DAY ONE BIOPHARMACEUTICALS INC
STX TANGO THERAPEUTICS
HOWL INC
APP SEAGATE TECHNOLOGY HLDGS PLC
TTD WEREWOLF THERAPEUTICS INC
QUBT APPLOVIN CORP
GFS THE TRADE DESK
GMTX INC.
TYRA QUANTUM COMPUTING INC
EWTX GLOBALFOUNDRIES INC
SLDB GEMINI THERAPEUTICS INC
DDI TYRA BIOSCIENCES INC
APGE EDGEWISE THERAPEUTICS INC
EMBRAC B SOLID BIOSCIENCES INC
DNTH DOUBLEDOWN INTERACTIVE CO LTD
CART APOGEE THERAPEUTICS INC
NATL EMBRACER GROUP AB
CGON DIANTHUS THERAPEUTICS INC
ORKA MAPLEBEAR INC.
BCAX NCR ATLEOS CORPORATION
ZBIO CG ONCOLOGY INC
TLX ORUKA THERAPEUTICS INC
MAZE BICARA THERAPEUTICS INC.
JBIO ZENAS BIOPHARMA INC.
TELIX PHARMACEUTICALS LIMITED
MAZE THERAPEUTICS INC
JADE BIOSCIENCES INC
- David Nierengarten
- Dennis Pak
- Geoffrey Von Der Ahe
- Laura Chico
- Martin Fan
- Robert Driscoll
- Thomas Yip
- Yun Zhong
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
FRX_CN FENNEC PHARMACEUTICALS
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
OVID OVID THERAPEUTICS
ISR ISORAY
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
STRO SUTRO BIOPHARMA
STOK STOKE THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
BEAM BEAM THERAPEUTICS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
GMTX GEMINI THERAPEUTICS INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
SLDB SOLID BIOSCIENCES INC
APGE APOGEE THERAPEUTICS INC
DNTH DIANTHUS THERAPEUTICS INC
ORKA ORUKA THERAPEUTICS INC
BCAX BICARA THERAPEUTICS INC.
ZBIO ZENAS BIOPHARMA INC.
TLX TELIX PHARMACEUTICALS LIMITED
MAZE MAZE THERAPEUTICS INC
JBIO JADE BIOSCIENCES INC
- Laura Chico
- Thomas Yip
- Laura Chico
- Thomas Yip
Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Bus...
Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update Phase 3 X-TOLE2 topline data for azetukalner in FOS expected first half of March 2026Five additional Phase 3 studies of azetukalner continue to enroll in epilepsy and neuropsychiatry indications with Phase 3 X-NOVA2 MDD topline data expected in H1 2027 Data from two Phase 1 studies of novel NaV1.7 (XEN1701) and KV7 (XEN1120) candidates expected in 2026 to support Phase 2 proof-of-concept studies in pain Pro forma cash of $716 million including recent ATM sales extends cash runway into second half of 2027Xenon...
Vericel Reports Fourth Quarter and Full-Year 2025 Financial Results
Vericel Reports Fourth Quarter and Full-Year 2025 Financial Results Total Revenue of $276.3 Million, with MACI Revenue Growth of 21% to $239.5 Million Net Income Growth of 59% to $16.5 Million Fourth Quarter Total Revenue and MACI Revenue Growth of 23% Record Fourth Quarter Gross Margin of 79% and Adjusted EBITDA Margin of 40% Conference Call Today at 8:30am Eastern Time CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today reported financial results and busines...
TopBuild Reports Fourth Quarter and Year-End 2025 Results, Provides 20...
TopBuild Reports Fourth Quarter and Year-End 2025 Results, Provides 2026 Outlook Fourth Quarter HighlightsFourth quarter sales totaled $1.49 billion, up 13.2% driven by acquisitionsCompleted SPI Acquisition Full Year HighlightsCompleted seven acquisitions, adding approximately $1.2 billion in annual salesReturned $434.2 million in capital to stockholders through the repurchase of ~1.4 million shares 2026 OutlookExpects 2026 sales between $5.925 to $6.225 billion andadjusted EBITDA in the range of $1.005 billion to $1.155 billionAcquisitions continue to be top priority for deploying capita...
ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financ...
ADMA Biologics Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update FY 2025 Total Revenue of $510 Million, Representing 20% Year-Over-Year Growth FY 2025 ASCENIV Revenue Grew to $363 Million, Representing 51% Year-Over-Year Growth FY 2025 Adjusted Net Income(1) of $161 Million, Representing 35% Year-Over-Year Growth FY 2025 Adjusted EBITDA(2) of $231 Million, Representing 40% Year-Over-Year Growth Incoming CFO Appointment Expected to Further Enhance Financial Strategy, Working Capital Execution and Capital Allocation Discipline Advancing SG-00...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
TTMI TTM TECHNOLOGIES INC.
PFG PRINCIPAL FINANCIAL GROUP INC.
LGIH LGI HOMES INC.
GTE GRAN TIERRA ENERGY
GOOD GLADSTONE COMMERCIAL CORPORATION
GLW CORNING INC
FAN FABRINET
FIX COMFORT SYSTEMS USA INC.
CUBE CUBESMART
CIEN CIENA CORPORATION
AXTI AXT INC.
AAOI APPLIED OPTOELECTRONICS INC.
COHU COHU INC.
OXM OXFORD INDUSTRIES INC.
RELL RICHARDSON ELECTRONICS LTD.
AEHR AEHR TEST SYSTEMS
UAA UNDER ARMOUR INC. CLASS A
TNDM TANDEM DIABETES CARE
FNKO FUNKO CLASS A
ST SENSATA TECHNOLOGIES HOLDING PLC
VICR VICOR CORP.
ATOM ATOMERA
MMMB MAMAMANCINI'S HOLDINGS INC
STNE STONECO
MRNA MODERNA INC.
ATEX ANTERIX INC
XP XP
PRDO PERDOCEO EDUCATION CORP
JAKK JAKKS PACIFIC INC.
SHLS SHOALS TECHNOLOGIES GROUP
COHR COHERENT CORP
SYRE SPYRE THERAPEUTICS INC.
LGCY LEGACY EDUCATION INC.
HOII REX HOOD GROWTH & INCOME ETF
MDLN MEDLINE INC
TopBuild to Acquire Johnson Roofing
TopBuild to Acquire Johnson Roofing DAYTONA BEACH, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- TopBuild Corp. (NYSE:BLD), a leading installer of insulation and commercial roofing and a specialty distributor of insulation and related building products to the construction industry in the United States and Canada, announced it has entered into an agreement to acquire Johnson Roofing, one of the largest commercial roofing installation services companies in Texas with approximately $29 million in annual revenue. Founded in 1941 in Waco, Johnson Roofing is a third generation roofing company servin...
Vulcan Materials Co: 1 director
A director at Vulcan Materials Co sold 1,137 shares at 303.720USD and the significance rating of the trade was 82/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.